Research library
Kisspeptin-10 Research Overview: KISS1R Pharmacology and Reproductive-Axis Study Evidence
- Compiled by:
- Peptide Pilots Scientific Content Team
- Reviewed by:
- Peptide Pilots Quality & Compliance review
- Last revised:
What has controlled human research established about Kisspeptin-10's effect on the reproductive hormone axis?
Kisspeptin-10 is the shortest fully active fragment of kisspeptin, a neuropeptide that acts on KISS1R-expressing GnRH neurons to trigger pulsatile GnRH, and downstream LH and FSH, release. Intravenous infusion studies in healthy volunteers and in people with reproductive endocrine disorders consistently report acute, dose-dependent increases in LH and, to a lesser extent, FSH. Investigational human work has extended to oocyte maturation triggering in IVF protocols and to studies in hypothalamic amenorrhoea and male hypogonadotropic states, but no kisspeptin formulation has regulatory approval, and most trials are small, single-centre, mechanistic infusion studies rather than large outcome trials.
This page is an educational literature summary for laboratory professionals. It is not medical advice, not a description of product performance, and it does not describe or endorse human or veterinary use. Materials referenced are supplied for controlled laboratory research only.
What is Kisspeptin-10?
Kisspeptins are peptide products of the KISS1 gene, cleaved into several C-terminally identical fragments (kisspeptin-54, -14, -13 and -10) that all retain full activity at their receptor, KISS1R (formerly GPR54).
Kisspeptin-10 is the minimal decapeptide fragment (residues 45-54 of kisspeptin/metastin) used experimentally because it is synthetically simple while retaining full receptor potency, making it the standard tool for human infusion studies of the kisspeptin-GnRH axis.
Kisspeptin-10 names and identifiers
Also referred to as: Metastin(45-54); KP-10; kisspeptin decapeptide
| Sequence | Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 (metastin 45-54) |
|---|---|
| Molecular formula | C63H83N17O14 |
| Average molecular weight | ≈1302.4 g/mol |
| Molecular target | Kisspeptin receptor (KISS1R / GPR54, UniProt Q969F8) |
| Gene of origin | KISS1 (originally identified as a metastasis-suppressor gene) |
| Registry records | ClinicalTrials.gov NCT00953355 and NCT02268786 (IVF trigger studies), among others |
Kisspeptin-10 research background
KISS1 was first identified in 1996 as a metastasis-suppressor gene; its receptor GPR54 was later renamed KISS1R once loss-of-function mutations were shown in 2003 to cause idiopathic hypogonadotropic hypogonadism, establishing kisspeptin signalling as essential for puberty and reproductive function.
Subsequent physiology work placed kisspeptin neurons in the arcuate and anteroventral periventricular hypothalamic nuclei as the principal upstream drivers of pulsatile GnRH secretion, integrating metabolic and steroid-feedback signals.
From around 2005, groups including the Dhillo/Bloom laboratory at Imperial College London began human intravenous infusion studies using kisspeptin-10, characterising its acute gonadotropin-releasing effects and exploring applications in reproductive medicine.
Proposed Kisspeptin-10 mechanisms and pathways
Evidence is separated by study type. In-vitro and animal findings describe model systems and do not establish equivalent behaviour in humans.
Kisspeptin-10 in-vitro and cell-based evidence
- Binds KISS1R, a Gq-coupled GPCR, activating phospholipase C and downstream signalling that depolarises GnRH neurons expressing the receptor.
- Receptor-binding and calcium-mobilisation assays in transfected cell lines confirm nanomolar potency for kisspeptin-10, consistent with full agonist activity relative to the longer native fragments.
Kisspeptin-10 animal-model evidence
- Rodent and primate studies established that central or peripheral kisspeptin administration triggers robust LH release, and that KISS1R knockout animals fail to undergo normal pubertal maturation.
- Animal studies also identified kisspeptin neurons as integrators of metabolic status (e.g. leptin signalling) and sex-steroid feedback onto the GnRH pulse generator.
Published Kisspeptin-10 human-study evidence
- Intravenous kisspeptin-10 infusion in healthy men and women produces dose-dependent LH release, with reported effects in women varying across the menstrual cycle in line with oestrogen-dependent GnRH-neuron sensitivity.
- Studies in women with hypothalamic amenorrhoea report that kisspeptin infusion can stimulate LH pulsatility, supporting a therapeutic-research rationale distinct from exogenous gonadotropin administration.
- Trials using kisspeptin as an oocyte-maturation trigger in IVF protocols report effective triggering of the LH surge with a lower reported risk of ovarian hyperstimulation syndrome compared with hCG triggers in high-risk populations, though sample sizes remain modest.
Published Kisspeptin-10 studies
| Study | Model / type | Research question | Main observation | Citation |
|---|---|---|---|---|
| Dhillo et al., first human infusion study | Human, healthy male volunteers, intravenous kisspeptin-54/kisspeptin-10 infusion | Does peripheral kisspeptin administration raise LH in humans? | Reported dose-dependent increases in LH and, to a lesser extent, FSH and testosterone following infusion. | Journal of Clinical Endocrinology & Metabolism, 2005 |
| Jayasena et al., hypothalamic amenorrhoea study | Human, women with hypothalamic amenorrhoea, kisspeptin-54 infusion | Can kisspeptin restore LH pulsatility in a reproductive disorder characterised by GnRH deficiency? | Reported increased LH pulse frequency during kisspeptin infusion relative to baseline. | Journal of Clinical Endocrinology & Metabolism, 2009 |
| Abbara et al., IVF oocyte-maturation trigger trial | Human, women undergoing IVF at high risk of ovarian hyperstimulation syndrome | Can kisspeptin trigger oocyte maturation as an alternative to hCG or GnRH agonist triggers? | Reported effective oocyte maturation with kisspeptin triggering and low observed rates of ovarian hyperstimulation syndrome. | Human Reproduction, 2017 |
Limitations of the Kisspeptin-10 evidence
- Most human data come from acute intravenous infusion studies in single-centre academic settings, predominantly from one research group, rather than multicentre randomised outcome trials.
- Effects are strongly modulated by sex-steroid status and menstrual-cycle phase, complicating dose comparisons across studies and populations.
- No kisspeptin-based product has been granted regulatory approval; work in IVF triggering and hypogonadotropic states remains investigational, with pregnancy and live-birth outcome data still limited relative to established hCG or GnRH agonist triggers.
- Kisspeptin-10 has a very short plasma half-life (on the order of minutes), which has driven interest in longer-acting analogues and limits interpretation of single-bolus study designs for any sustained physiological effect.
- Given KISS1's original identification as a metastasis-suppressor gene, the systemic long-term safety implications of pharmacological KISS1R agonism outside short infusion studies have not been thoroughly characterised.
Kisspeptin-10 laboratory characteristics
Handling and analytical information reported in the literature and in supplier documentation. Values apply to laboratory materials and are not directions for any other use.
| Appearance | White to off-white lyophilised powder |
|---|---|
| Solubility | Soluble in water or dilute acetic acid; a short, hydrophilic amidated decapeptide |
| Lyophilised storage | Commonly stored at −20 °C, desiccated and protected from light |
| Reconstituted handling | Kept cold and used promptly in infusion-study protocols owing to short plasma half-life |
| Analytical testing | RP-HPLC purity and MS identity are the standard reagent-grade checks reported by suppliers and used in clinical-trial formulation |
| Stability considerations | The C-terminal amide and short chain length make it relatively stable when kept cold and dry; degradation studies focus on peptidase susceptibility |
Frequently asked Kisspeptin-10 research questions
How does Kisspeptin-10 differ from the full-length kisspeptin peptides?
Kisspeptin-54, -14, -13 and -10 share an identical C-terminal decapeptide sequence and are all full agonists at KISS1R; kisspeptin-10 is simply the shortest fragment retaining full potency, which makes it convenient for synthesis and infusion studies.
What is KISS1R, and why does it matter for reproduction?
KISS1R is a G-protein-coupled receptor expressed on GnRH neurons. Loss-of-function mutations in the receptor cause failure to enter puberty (idiopathic hypogonadotropic hypogonadism), establishing kisspeptin signalling as an essential upstream trigger for the GnRH pulse generator.
Has kisspeptin been used clinically in IVF?
It has been studied as an investigational trigger for oocyte maturation, particularly in women at high risk of ovarian hyperstimulation syndrome, in academic trials; it is not an approved standard-of-care trigger agent.
Why is kisspeptin-10's short half-life relevant to interpreting studies?
Because plasma clearance occurs within minutes, most human data reflect acute bolus or short-infusion pharmacodynamics rather than sustained steady-state exposure, which limits extrapolation to other dosing regimens.
Kisspeptin-10 primary references
- Dhillo WS, Chaudhri OB, Patterson M, et al. (2005). Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2005-1361
- Jayasena CN, Nijher GM, Abbara A, et al. (2009). Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of kisspeptin-54. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2009-0552
- Abbara A, Clarke SA, Islam R, et al. (2017). A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a phase 2 randomized controlled trial. Human Reproduction. https://doi.org/10.1093/humrep/dex114
Authorship and revision
Compiled from primary literature and public databases. Every factual statement on this page is traceable to a listed reference. Compiled by Peptide Pilots Scientific Content Team; documentation and compliance review by Peptide Pilots Quality & Compliance review. First published ; last revised . Pages are revised when the cited literature changes materially.
Related catalogue products
Laboratory reagents supplied by Peptide Pilots from the Reproductive & Sexual-Health Research tier. Research use only; not for human or veterinary use.
